

Multiplexed immunofluorescence imaging reveals an immune rich tumor microenvironment in mucinous rectal cancer characterized by increased lymphocyte infiltration and enhanced PD-1 expression

AUTHOR(S)

William Duggan, Batuhan Kisakol, Emer O'Connell, Anna Matveeva, Anthony O'Grady, Elizabeth McDonough, Andreas Lindner, Deborah McNamara, Daniel Longley, Fiona Ginty, John Burke, Jochen Prehn

CITATION

Duggan, William; Kisakol, Batuhan; O'Connell, Emer; Matveeva, Anna; O'Grady, Anthony; McDonough, Elizabeth; et al. (2023). Multiplexed immunofluorescence imaging reveals an immune rich tumor microenvironment in mucinous rectal cancer characterized by increased lymphocyte infiltration and enhanced PD-1 expression. Royal College of Surgeons in Ireland. Journal contribution.
<https://hdl.handle.net/10779/rcsi.21995705.v1>

HANDLE

[10779/rcsi.21995705.v1](https://hdl.handle.net/10779/rcsi.21995705.v1)

LICENCE

CC BY-NC 4.0

This work is made available under the above open licence by RCSI and has been printed from <https://repository.rcsi.com>. For more information please contact repository@rcsi.com

URL

https://repository.rcsi.com/articles/journal_contribution/Multiplexed_immunofluorescence_imaging_reveals_an_immune_rich_tumor_microenvironment_in_mucinous_rectal_cancer_characterized_by_increased_lymphocyte_infiltration_and_enhanced_PD-1_expression/21995705/1

Variable		Non-Mucinous RC(N=43)	Mucinous RC (N=15)	p Value
Male		58.1% (25)	53.3 % (8)	0.75
Age	Median (IQR)	70(42-89)	71 (29-81)	0.10
Stage	AJCC 1	11.6% (5)	13.3% (2)	0.17
	AJCC 2	34.8% (15)	60.0% (9)	
	AJCC 3	53.4%(23)	26.0% (4)	
	AJCC4	0.0%(0)	0.0% (0)	
T Stage	Tis-T1-T-2	25.5% (11)	20.0% (3)	0.28
	T3	65.1% (28)	60.0% (9)	
	T4	9.3% (4)	20.0% (3)	
N Stage	N0	48.8% (21)	73.3% (11)	0.52
	N1	41.8%(18)	6.7% (1)	
	N2	9.3%(4)	20.0% (3)	
M Stage	M0	100% (43)	100% (15)	NA
	M1	0.0% (0)	0.0% (0)	
Neoadjuvant CRT(n=56)^a		69.8% (30)	53.3% (8)	0.32
Adjuvant CRT (n=52)^a		39.5% (17)	53.3% (8)	0.26
MSI (n=55)^a		2.4% (1)	14.3%(2)	0.09
KRAS (n=55)^a	Mutant	17.1%(7)	35.7%(5)	0.15
BRAF (n=54)^a	Mutant	2.4% (1)	7.7%(1)	0.38
LVI (n=57)^a		19%(8)	6.7%(1)	0.26
Perineural Invasion(n=56)^a		11.9%(5)	14.3%(2)	0.82
Extramural Invasion(n=56)^a		19.0%(8)	7.1%(1)	0.29
DFS (Months)	Mean(SD)	47(26.1)	46(30.2)	0.97
DSS(Months)	Mean(SD)	52(24.1)	55(33.5)	0.63

Table 2. Clinical and pathological profile of mucinous and non-mucinous rectal cancers.

AJCC American Joint Committee on Cancer, CRT Chemoradiotherapy, DFS Disease Free Survival, DSS Disease Specific Survival, LVI Lymphovascular Invasion, SD Standard Deviation. Categorical data reported as % (n). ^a Data not available in full cohort: n in parentheses = number with data available.